---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Executive summary: Disease burden"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Disease burden. Topics: Summary: definition, etiology, and diagnosis; Summary: US prevalence and incidence; Summary: natural history and mortality by fibrosis stage; Summary: long-term morbidity; 2 further topics. 6 evidence topics quoted from 53 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary/disease-burden"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Executive summary: Disease burden

<a id="heading-1.1.1"></a>

## 1.1.1 Burden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

<a id="topic-1.1.1-1"></a>

### Summary: definition, etiology, and diagnosis

Under the revised nomenclature, metabolic dysfunction-associated steatotic liver disease (MASLD) replaced nonalcoholic fatty liver disease (NAFLD), chosen by 75% of respondents of the external expert committee, and metabolic dysfunction-associated steatohepatitis (MASH) replaced nonalcoholic steatohepatitis (NASH), chosen by 88%. MASLD is defined as hepatic steatosis with at least one cardiometabolic risk factor and no other discernible cause. Disease staging is unchanged, and 98% of a European registry cohort with NAFLD fulfilled the MASLD criteria; in a US national study, 99.0% (95% CI 97.6% to 99.6%) of adults with NAFLD or MASLD met the criteria for both. The 2023 AASLD practice guidance defines at-risk NASH as biopsy-proven NASH with stage 2 or higher fibrosis. The European Association for the Study of the Liver (EASL) guideline names type 2 diabetes and obesity as the metabolic diseases with the strongest impact on progression to advanced fibrosis, cirrhosis, and hepatocellular carcinoma, and identifies the PNPLA3 p.I148M and TM6SF2 p.E167K variants as major risk factors; the heritable component of NAFLD and NASH is estimated at 35% to 61%.

NAFLD is asymptomatic or associated with vague symptoms in most patients, and patients are most commonly referred with incidentally noted hepatic steatosis on imaging or elevated liver chemistries. In US cross-sectional surveys of physicians and consulting patients with suspected or confirmed MASH in 2019 and 2022, no sign or symptom was reported for 167 patients (39.4%) overall; fatigue was reported for 230 (54.2%) overall and for 70 (85.4%) in the AASLD-derived high-risk category.

Liver biopsy is the reference standard for grading and staging but has limitations related to risk, cost, and resource utilization, and none of the noninvasive methods can assess ballooning or lobular inflammation. Guidelines use a fibrosis-4 index (FIB-4) below 1.3 to identify low risk, with follow-up in primary care, and FIB-4 of 1.3 or higher to prompt secondary assessment with vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test; FIB-4 above 2.67 indicates high risk, and the EASL guideline states that FIB-4 will miss around 10% of individuals with advanced fibrosis. A VCTE liver stiffness below 8 kPa can rule out advanced fibrosis, and above 12 kPa is associated with a high likelihood of advanced fibrosis. Aminotransferase levels are frequently normal in advanced disease. The AASLD guidance updates state that no FDA-approved noninvasive test diagnoses MASH with F2 to F3 or monitors response, that the resmetirom label does not require biopsy, and that semaglutide candidates with stage 2 to 3 fibrosis can be identified by VCTE (8 to 15 kPa), magnetic resonance elastography (3.1 to 4.4 kPa), or ELF (9.2 to 10.5).

Diagnosis rates are low. A US population calculator cites a diagnosis rate of ~10% (range 3.3% to 14.3%) of the treatment-eligible population, and NHANES survey responses indicate that 14.3% of prevalent patients with F2 to F3 NASH have received a diagnosis of liver disease. The 2016 prevalence of diagnosed NASH among US adults was 0.15%. In NHANES 2017 to 2023, awareness of liver disease was 5.8% (pre-pandemic) and 6.7% (late pandemic) among adults with MASLD, and 12.1% and 10.3% among adults with MASLD and liver stiffness of 8 to 15 kPa.

Source: [Rinella et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10653297/); [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Loomba et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12168897/); [Shinde et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12519272/); [Chen et al. (2025)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001112~resmetirom-therapy-for-metabolic-dysfunction-associated); [Bansal et al. (2026)](https://journals.lww.com/hep/fulltext/10.1097/hep.0000000000001608~semaglutide-therapy-for-metabolic-dysfunctionassociated); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [Alp et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12520227/)

<a id="topic-1.1.1-2"></a>

### Summary: US prevalence and incidence

Estimates differ by the population counted, the definition, and the method:

- Steatotic liver disease and MASLD, US adults, national study: steatotic liver disease 34.2% (more than 90 million US adults), MASLD 31.3%. In NHANES 2017 to 2023, the age-adjusted prevalence of MASLD was 31.9%.
- MASLD by liver stiffness: of 2,691 NHANES 2017 to 2020 participants with MASLD, projecting to 75.8 million US adults, 11% had liver stiffness of 8 to 12 kPa and 6% of 12 kPa or higher.
- At-risk NASH (NAFLD activity score of 4 or more and fibrosis stage 2 or higher, estimated by FibroScan-AST score above 0.35): overall prevalence 11.6% (95% CI 8.8 to 15.1), higher in males than in females (15.8% and 6.5%); the authors estimated ~9 million people in the US have at-risk NASH.
- Adults meeting resmetirom eligibility criteria defined by ALT, controlled attenuation parameter, and liver stiffness: 8.3 million (liberal criteria) and 2.3 million (restrictive criteria).
- Adults aged 50 years or older with type 2 diabetes in a southern California cohort, 2016 to 2023: MASLD 69.6%, at-risk MASH 13.6%, cirrhosis 6.8%.
- Modeled NASH with F2 to F3 fibrosis: an eligible-population model applied a NASH prevalence of 4.6% (range 1.3% to 14.2%) and a non-cirrhotic F2 to F3 proportion of 35%, yielding 1,255 to 1,699 treatment-eligible patients per 1 million commercial members in Years 1 to 3. The ICER budget impact analysis applied a prevalence of 1.4% to US adults aged 18 and older (4% NASH multiplied by 35% with moderate to severe fibrosis), an average of 3.81 million eligible patients.
- Modeled trends: one model projected cases of MASH with F2 or higher fibrosis to increase from 6.7 million in 2020 to 11.7 million by 2050, and MASH cases from 14.9 million (5.8% of US adults) to 23.2 million (7.9%). Another projected NASH cases to increase from 16.52 million in 2015 to 27.00 million in 2030, with NASH with F3 to F4 fibrosis increasing from approximately 3.31 million (20% of NASH cases) to 7.94 million (29%). A third estimated 6.65 million US adults with NASH and 232,000 incident cases in 2017.
- Incidence: one analysis projected 73,085 newly coded US patients with F2 to F3 NASH in 2020, a rate of 28.4 cases per 100,000 adults (other analyses 20.4 to 64.0 per 100,000 adults). Across 54 studies, 31% of patients developed NASH after 4.7 years (7.4 per 100 person-years).

Source: [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11232657/); [Kim et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12016658/); [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/); [Payne et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9833447/); [Le et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12180822/); [Mittal et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12425555/); [Fishman et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11480167/); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Le et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11742522/); [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/); [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/)

<a id="topic-1.1.1-3"></a>

### Summary: natural history and mortality by fibrosis stage

Fibrosis and steatohepatitis are the primary predictors of progression, and patients with NASH and at least stage 2 fibrosis have a higher risk of liver-related morbidity and mortality. In 14 articles of cohort studies involving 17,301 patients with biopsy-proven NAFLD, all-cause mortality hazard ratios compared with stage 0 were 1.46 for stage 2, 1.96 for stage 3, and 3.66 for stage 4, and liver-related mortality hazard ratios were 4.07, 7.59, and 15.1. Among 1,495 patients with NAFLD (17,452 patient years of follow-up), mortality rate ratios for stages 2 and 3 were 2.52 and 3.48 for all-cause mortality and 9.57 and 16.69 for liver-related mortality. Among 1773 adults with NAFLD followed for a median of 4 years, all-cause mortality was 0.32 deaths per 100 person-years for F0 to F2, 0.89 for F3, and 1.76 for F4, and any hepatic decompensation event was associated with increased all-cause mortality (adjusted hazard ratio 6.8). In a cohort of 1,260 patients with NAFLD without cirrhosis followed for a median of 13 years, the 20-year cumulative incidence of major adverse liver outcomes was 3% for F0 and 35% for F3, with adjusted hazard ratios of 2.9 for biopsy-determined F2 and 8.9 for F3 compared with F0 to 1. In a cohort analysis supported by Novo Nordisk Inc., incidence rates of cirrhosis were 0.34/100PM for F0 to F1, 1.24/100PM for F2 (281 patients), and 6.62/100PM for F3 (162 patients), and all-cause mortality rates were 0.14, 0.3, and 0.42/100PM.

A pooled analysis of 54 studies estimated the time to progress by one fibrosis stage at 13.3 years from F2 and 22.2 years from F3; after 5 years, 32% of patients with F2 progressed, 37% regressed, and 31% remained stable, and patients with F3 regressed more often than they progressed (32% and 22%). In a Swedish nationwide cohort of 10,568 individuals with biopsy-confirmed NAFLD, non-cirrhotic fibrosis was associated with excess mortality compared with controls (18.4/1000PY, aHR 2.44), and the excess mortality was primarily from extra-hepatic cancer. Cardiovascular disease and nonhepatic malignancy are the most common causes of death in NAFLD, followed by liver disease. One projection estimated that NAFLD-related incident decompensated cirrhosis would increase from 39,320 cases in 2015 to 105,430 in 2030, incident hepatocellular carcinoma from 5,160 to 12,240, and liver deaths to 78,300 in 2030. According to CDC FastStats, chronic liver disease and cirrhosis of all causes accounted for 52,274 US deaths (15.4 per 100,000 population), the ninth-ranked cause of death.

Source: [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Ng et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10792524/); [Dulai et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5397356/); [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/); [Akbari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10827505/); [Luthra and Sheth (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11787050/); [Le et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9898457/); [Simon et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8185553/); [Estes et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5767767/); [CDC FastStats chronic liver disease and cirrhosis (2026)](https://www.cdc.gov/nchs/fastats/liver-disease.htm)

<a id="topic-1.1.1-4"></a>

### Summary: long-term morbidity

The prevalence of cirrhosis in the United States is 2.6%, and individuals with MASLD comprise the majority of US residents with cirrhosis (MASLD-cirrhosis 1.27% of the general population). Among patients with cirrhosis, progression to clinical decompensation ranges from 3% to 20% per year. In the cohort of 1773 adults with NAFLD, incidence per 100 person-years for F0 to F2, F3, and F4 was 0.04, 0.52, and 1.20 for ascites, 0.02, 0.75, and 2.39 for encephalopathy, and 0.04, 0.34, and 0.14 for hepatocellular cancer. Among 296,707 US veterans with NAFLD, hepatocellular carcinoma incidence was 0.21/1000 PY compared with 0.02/1000 PY in matched controls (hazard ratio 7.62), and 20% of patients with NAFLD and hepatocellular carcinoma had no evidence of cirrhosis; across 61 studies, 38.5% of NAFLD-related hepatocellular carcinoma occurred without cirrhosis. The EASL guideline states that individuals with F3 fibrosis have an intermediate risk of hepatocellular carcinoma and that surveillance may be considered for them. NASH/MASH increased from 9% to 28% of US liver transplant recipients from 2000 to 2022, and 44.5% of 65,675 US adults on the liver transplant waitlist for steatotic liver disease from 2010 to 2023 had MASH.

NAFLD was associated with an increased risk of fatal or non-fatal cardiovascular events (pooled HR 1.45), which increased with fibrosis stage (pooled HR 2.50), and with incident chronic kidney disease (HR 1.43). In the cohort of 1773 adults with NAFLD, new-onset hypertension (7.8 events per 100 person-years) and type 2 diabetes (4.8 events per 100 person-years) were the most common new nonhepatic outcomes. NAFLD was associated with a nearly 1.5-fold to twofold increased risk of gastrointestinal cancers.

Source: [Younossi et al. (2025c)](https://pubmed.ncbi.nlm.nih.gov/39879587/); [Rinella et al. (2023a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10735173/); [Sanyal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8881985/); [Kanwal et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6279617/); [Tan et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9718369/); [European Association for the Study of the Liver (2024)](https://www.journal-of-hepatology.eu/article/S0168-8278%2824%2900329-5/fulltext); [Younossi et al. (2026a)](https://pubmed.ncbi.nlm.nih.gov/40674288/); [Patel et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11869966/); [Mantovani et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34555346/); [Mantovani et al. (2022a)](https://pubmed.ncbi.nlm.nih.gov/33303564/); [Mantovani et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/33685968/)

<a id="topic-1.1.1-5"></a>

### Summary: humanistic burden

In the 2016 US National Health and Wellness Survey, 136 adults with physician-diagnosed NASH reported lower mental (43.19 and 46.22) and physical (42.04 and 47.10) component scores than 544 matched adults from the general population, and higher proportions with anxiety (37.5% and 25.5%) and depression (43.4% and 30.1%). Among 713 adults with NAFLD in the NASH Clinical Research Network, physical health scores were 44.6 with moderate or bridging fibrosis and 38.4 with cirrhosis, and mental health scores did not differ by degree of fibrosis. Among 1667 adults with NASH and F3 or F4 fibrosis at baseline of the STELLAR trials, patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4 of 8 SF-36 domains compared with the general population; 33% and 27% of 1,669 patients had fatigue and pruritus.

In the GAIN study, mean EQ-5D index values in the United States were 0.80 for early (F0 to F2) and 0.67 for advanced (F3 to F4) fibrosis, and across all countries 0.80 and 0.62; mean CLDQ-NAFLD index values in the United States were 4.7 and 4.0. The baseline mapped EQ-5D utility of 800 participants with biopsy-confirmed MASH and F2 or F3 fibrosis in a trial of semaglutide 2.4 mg or placebo was ∼0.78, with group means of 0.783 and 0.789 for stage 2 and 0.792 and 0.769 for stage 3. In a phase 2 trial of 392 patients with bridging fibrosis or compensated cirrhosis, those with fibrosis improvement of at least one stage at week 48 had improvement in EQ-5D and five of six CLDQ-NASH domains. Across 25 publications covering 23 unique studies, all evaluable studies had inadequate control of confounders, and in a meta-analysis, three studies of increasing fibrosis and quality of life had inconsistent findings.

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [David et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2692572/); [Younossi et al. (2019b)](https://pubmed.ncbi.nlm.nih.gov/30779990/); [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/); [Younossi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8279457/); [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/); [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

<a id="topic-1.1.1-6"></a>

### Summary: economic burden, caregiver costs, and diagnostic testing

Annual direct medical costs of NAFLD in the United States were estimated at about $103 billion ($1,613 per patient) for over 64 million people, and lifetime costs of all US patients with NASH in 2017 at $222.6 billion, of which $95.4 billion for the advanced NASH population. In the GAIN study of 3,754 patients with NASH in 2018, the mean total annual per-patient cost was €2,763 direct medical, €4,917 direct non-medical, and €5,509 indirect; NASH-related direct medical costs were €2,224 for early and €3,983 for advanced fibrosis (€4,881 in the USA), and indirect costs were €5,939 and €12,642. Professional (34%) and informal (48%) caregivers accounted for most direct non-medical costs, and these percentages increased with fibrosis stage; patient-reported non-medical costs were €1,704 for early and €4,661 for advanced fibrosis.

Modeled annual costs by health state differ by source. The ICER model used annual costs of $7,063 for F0 to F2, $8,423 for F3, $34,275 for compensated cirrhosis, $158,480 for decompensated cirrhosis, and $115,002 for hepatocellular carcinoma. A model funded by Siemens Healthcare Diagnostics Inc used annual direct medical costs (2025 USD) of $1,180 for F2-3, $23,360 for compensated cirrhosis, and $36,290 for decompensated cirrhosis.

In linked electronic health record and claims data, mean annual costs among 6,743 adults with NASH increased from $16,744 to $34,667 between the lowest and highest FIB-4 cohorts, and each one-unit increase in FIB-4 was associated with a 3.4% increase in mean total annual cost. Among 251,725 commercially insured adults, total all-cause costs increased by 17% to 29% after identification of FIB-4-based F3 fibrosis and by 47% to 48% for F4. Among 485,774 commercially insured adults with NAFLD or NASH, adjusted annual costs were $23,860 without advanced liver disease, $29,078 with compensated cirrhosis, $134,448 with decompensated cirrhosis, $197,392 with liver transplant, and $97,563 with hepatocellular carcinoma. Compared with the matched general population, adults with NASH reported more health care provider visits (8.43 and 5.17), hospitalizations (0.43 and 0.21), and overall work impairment (39.6% and 26.2%). One model estimated that a hypothetical therapy halting fibrosis progression in MASLD would avert $40.5 to $99.1B in incremental health care costs.

One prior authorization policy for resmetirom and semaglutide requires documentation of F2 or F3 fibrosis by liver biopsy within 3 years, VCTE or magnetic resonance elastography within 6 months, or an ELF score of 9.2 to 10.5 within 6 months. Unit costs in the diagnostics manufacturer-funded model were $200 for a one-time ELF screening test, $257 for a hepatology consultation, $32 for transient elastography, $323 for MRI or CT, and $354 for liver biopsy. When the current FIB-4-based guideline was applied to NHANES data, 18.1 million VCTE examinations would be needed to diagnose 3.5 million US adults with MASLD and liver stiffness of 8 kPa or higher. Among 8,366 primary care patients with type 2 diabetes or prediabetes, 2,064 (25%) had FIB-4 values needing confirmatory risk assessment, 9.1 times the number with a MASLD diagnosis. In a US modeling study, screening strategies for high-risk MASLD added $13,587 to $14,730 per patient with type 2 diabetes compared with no screening. In the GAIN study, 697 (57%) US patients had a liver biopsy and 157 (13%) received transient elastography.

Source: [Younossi et al. (2016b)](https://pubmed.ncbi.nlm.nih.gov/27543837/); [Younossi et al. (2019a)](https://pubmed.ncbi.nlm.nih.gov/30180285/); [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/); [ICER Final Evidence Report, resmetirom and obeticholic acid for NASH (2023)](https://icer.org/wp-content/uploads/2025/01/NASH-Final-Report_Updated_011025.pdf); [Chen et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13087396/); [Tapper et al. (2023a)](https://pubmed.ncbi.nlm.nih.gov/36866575/); [Gordon et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7327220/); [Wong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8500367/); [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/); [Wallace et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39832655/); [Cigna Rezdiffra prior authorization policy (2026)](https://a.static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_852_coveragepositioncriteria_hepatology_rezdiffra_pa.pdf); [Kim et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12832100/); [Patel et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13094816/); [Younossi et al. (2025a)](https://pubmed.ncbi.nlm.nih.gov/39373093/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
